Business
Moderna will not commit to previous 2028 breakeven guidance as the ripple effects of the FDA’s refusal-to-file decision spread through its pipeline.
FEATURED STORIES
The rare disease drugmaker is facing potential competitors for achondroplasia drug Voxzogo. Is a big M&A deal with two approved assets enough to maintain investor interest?
A rapturous response to data published last year for Pelage’s hair loss candidate overwhelmed the biotech. Now, the company is ready to show the world the science behind the breakthrough.
Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
New Orleans-based Revolo Biotherapeutics, formerly known as Immune Regulation, rebranded to reflect its revolutionary scientific approach to dramatically alter the autoimmune and allergic disease treatment landscape.
Multiple pharmaceutical companies struck large licensing deals with one another this week. Here’s a look.
It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.
Aktis Oncology launched today with significant financing in hand to advance a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company’s launch was supported by pharma giants including Bristol Myers Squibb and Novartis.
The U.S. Attorney’s Office for Massachusetts charged Ishtiaq Ali Saaem, 37, with obstruction of justice for lying about his attempts to acquire 100 castor bean packets in order to develop the bioterror poison ricin. The acquisition was not recent, it took place on June 24, 2015.
In recent years, AI-fueled drug discovery programs have risen dramatically, particularly in regard to rare diseases.
Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, has entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
Another bluebird bio executive is jumping ship. Chief Medical Officer David Davidson is leaving the company on April 16.
BioSpace recently spoke with Sanjeev Luther, CEO and board member of Rafael Pharmaceuticals, a clinical-late stage metabolic therapeutics company.